Prelude Therapeutics Inc (PRLD)

Jan 13, 2025

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN

Jan 13, 2025

Jan 11, 2025

A Look At The Behavior Of Prelude Therapeutics Inc (PRLD) Stock - Stocks Register

Jan 11, 2025

Jan 11, 2025

Geode Capital Management LLC Grows Stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jan 11, 2025

Jan 10, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stake Lifted by Barclays PLC - Defense World

Jan 10, 2025

Jan 04, 2025

State Street Corp Raises Stock Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jan 04, 2025

Jan 03, 2025

Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock - Investing.com India

Jan 03, 2025

Jan 03, 2025

Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock By Investing.com - Investing.com UK

Jan 03, 2025

Jan 02, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $12,000 in stock - Investing.com

Jan 02, 2025

Jan 02, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares - MarketBeat

Jan 02, 2025

Dec 26, 2024

Insider Buying: Andrew Combs Acquires 63,075 Shares of Prelude T - GuruFocus.com

Dec 26, 2024

Dec 26, 2024

Andrew Combs Purchases 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat

Dec 26, 2024

Dec 22, 2024

XTX Topco Ltd Makes New $100,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Dec 22, 2024

Dec 22, 2024

Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics - Yahoo Finance UK

Dec 22, 2024

Dec 20, 2024

Insider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Purchases 100,000 Shares of Stock - MarketBeat

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Purchases $22,750.00 in Stock - MarketBeat

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics’ interim CFO Bryant Lim buys $22,637 in stock By Investing.com - Investing.com Nigeria

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com India

Dec 20, 2024

Dec 20, 2024

Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com

Dec 20, 2024

Dec 19, 2024

Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo

Dec 19, 2024

Dec 16, 2024

What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register

Dec 16, 2024

Dec 15, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada

Dec 15, 2024

Dec 14, 2024

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo

Dec 14, 2024

Dec 13, 2024

PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 13, 2024

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo

Dec 13, 2024

Dec 12, 2024

Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo

Dec 12, 2024

Dec 12, 2024

Prelude Therapeutics presents first interim data from trial of PRT2527 - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Position Increased by Walleye Capital LLC - Defense World

Dec 12, 2024

Dec 11, 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 - The Bakersfield Californian

Dec 11, 2024

Dec 11, 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

Sirus Therapeutics announces positive signals from Phase I siRNA trial - Yahoo Finance

Dec 10, 2024

Dec 05, 2024

PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges - Investing.com Nigeria

Dec 05, 2024

Nov 29, 2024

November 2024's Top Picks: Penny Stocks On US Exchanges - Simply Wall St

Nov 29, 2024

Nov 27, 2024

After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) - Yahoo Finance

Nov 27, 2024

Nov 27, 2024

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Yahoo Finance

Nov 27, 2024

Nov 25, 2024

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health - TipRanks

Nov 25, 2024

Nov 21, 2024

Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism - MyChesCo

Nov 21, 2024

Nov 21, 2024

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo

Nov 21, 2024

Nov 20, 2024

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN

Nov 20, 2024

Nov 17, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 15, 2024

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com Australia

Nov 14, 2024

Nov 13, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com

Nov 13, 2024

Nov 12, 2024

Tectonic Therapeutic Inc. Reports Q3 2024 Results - Yahoo Finance

Nov 12, 2024

Nov 12, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 10, 2024

Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 10, 2024